New hope for rare lung cancer mutations: targeted pill shows promise
NCT ID NCT04504071
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This study tests a daily pill called dacomitinib in 30 people with advanced lung cancer that has uncommon EGFR gene mutations. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug until their cancer worsens or they no longer benefit, and are followed for up to 4 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest hospital
Shanghai, Shanghai Municipality, 200030, China
Conditions
Explore the condition pages connected to this study.